Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 180

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 180
---
 in key indications, but were discontinued, largely due to safety and limited therapeutic index. Importantly, we prioritized the ability to be in the clinic quickly, and we expect to file INDs in the next 12 to 24 months, starting with our PTK7-directed asset in the second half of 2025, followed closely by the MUC16-directed asset by the end of 2025, and the SEZ6-directed asset in mid-2026.

| • |     | PTK7-CPT113 presents a differentiated opportunity to be among the first next wave ADCs in clinical                 
 development for high PTK7 expressing cancers, including NSCLC, ovarian cancer and several other major indications. |

| • |     | mMUC16-CPT113 is potentially the first ADC that targets membrane-bound portion of MUC16, a                                                   
 glycoprotein often overexpressed in cancers of female origin, such as ovarian cancer, endometrial cancer, cervical cancer, or breast cancer. |

| • |     | biSEZ6-CPT113 is designed to bind to two epitopes on the target SEZ6, which is often                                                                          
 overexpressed in cancers of neuroendocrine origin. We believe this biparatopic approach can potentially improve internalization and effectiveness of the ADC. |

- 117 -

We believe that improving ADC architecture can increase treatment efficacy in solid tumors. Each of the
three ADC assets utilizes the advanced CPT113 linker-payload technology from Hangzhou DAC, which consists of a highly stable yet cleavable linker that delivers a TOPO1 inhibitor payload, and high affinity antibodies designed using the
industry-leading antibody capability of Wuxi Biologics. We believe these assets have greater target binding, improved linker-payload stability, optimized pharmacokinetic parameters, together which can increase tumor cell killing and reduce off-target effects and can potentially overcome the limitations that hindered the first generation ADC therapies against these targets to deliver improved results for patients. Under the License Agreement, we have
worldwide development and commercialization rights to all of our product candidates. See “The PIPE Financing and License Agreement—The License Agreement.” We intend to develop each of our programs as a monotherapy and
also in combination with other therapies.

Industry Background

Antibody-Drug Conjugates

An antibody-drug conjugate
(“ADC”) consists of an antibody that is connected to a drug (the payload) via a linker. An ADC can be a preferred alternative to systemic chem